Eli Lilly’s experimental obesity pill orforglipron has succeeded in its third Phase 3 trial, positioning the company to file for global regulatory approval later this year. The results highlight both significant weight loss and meaningful blood sugar improvements in patients with obesity and type 2 diabetes. Strong Results in Difficult-to-Treat Population The latest trial, ATTAIN-2 … Eli Lilly’s Oral GLP-1 Weight-Loss Pill Clears Third Phase 3 Trial, Bringing FDA Approval Within Reach Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.